Show results for
Refine by
Applications
- 3D bioprinting technology for breast disease
- 3D bioprinting technology for lung disease
- 3D bioprinting technology for brain disease
- 3D bioprinting technology for liver disease
- 3D bioprinting technology for skin disease
- 3D bioprinting technology for pancreas disease
- 3D bioprinting technology for prostate disease
T Cell Subtypes From Naive T Cells Equipment Supplied In Australia
14 equipment items found
by:Carina Biotech based inMawson Lakes, AUSTRALIA
Carina Biotech's proprietary manufacturing process leads to a greater efficiency in CAR-T cell ...
by:Carina Biotech based inMawson Lakes, AUSTRALIA
Antigen-binding domain, Optimised linker domain, CD8-derived transmembrane domain, 4-1BB co-stimulatory domain, CD3 zeta stimulatory domain, Engineered chemokine ...
Manufactured by:Lipotek based inActon, AUSTRALIA
Lipovax-Fg115 is an adjuvanted delivery vehicle for recombinant antigens. The platform exploits the commonly used his-tag to attach multiple copies of one or more type of antigens to the surface Lipovax-Fg115 particles. Our proprietary Fg115 molecules are also attached to the liposomes to stimulate the TLR5 receptor. The platform improves vaccine internalisation by dendritic cells and results in ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
T cells are part of our adaptive immune system – the system that tailors the body’s response to specific pathogens. Rather than generically attack any antigens, T cells circulate until they encounter a specific antigen, playing a critical part in immunity to foreign ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
CAR T-cell therapy is the engineering of a patient’s T cells, a type of white blood cell. A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen receptors (CAR’s) on the cell surface. The chimeric antigen receptors give T cells the ability to target cancer cells. They comprise two specific components: one, an ...
Manufactured by:Inventia Life Science Pty Ltd (ILS) based inAlexandria, AUSTRALIA
We’re not chasing pipe dreams about printed organs. Our core technology in digital bioprinting is built for fast, scalable and reproducible printing of 3D cell constructs that you can ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, ...
by:Carina Biotech based inMawson Lakes, AUSTRALIA
Advanced colorectal cancer currently has a poor prognosis and is the deadliest form of cancer for Australians 25 to 34 years old. LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer and other cancers. In colon cancer patients, LGR5+ expression has been correlated with a particularly poor ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers that has been achieved today. Under the Collaboration ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-300-IV is being developed for the treatment of diabetic complications, including diabetic kidney disease known as diabetic ...
Manufactured by:Biotron Limited based inNorth Ryde, AUSTRALIA
Biotron is developing novel small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and ...